Skip to content

Study · Observational study · 2014

11 results

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.

Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C, Melchiorri D, Pani L

Nutrition, metabolism, and cardiovascular diseases : NMCD6 Oct 2014Cited by 33 (Europe PMC)

PMID25300980 (opens in a new tab)DOI10.1016/j.numecd.2014.07.014 (opens in a new tab)PepBankPUB-25300980
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studySafety outcome

    In the Italian diabetes registry, six acute pancreatitis cases occurred during exenatide treatment.

    In plain wordsIn the diabetes registry, six pancreatitis cases occurred among patients treated with exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableAcute pancreatitis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Acute pancreatitis cases
    6 cases
    on exenatide

    Source sentences

    Summary
    Overall, 1116 suspected adverse drug reactions were registered, including 12 cases of acute pancreatitis (six on exenatide).
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.
  2. 02HumanObservational studyOther

    In the Italian registry, treatment failure led to discontinuation in 7.7% of exenatide cases.

    In plain wordsIn the registry, 7.7% of exenatide cases stopped treatment because it failed.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableDiscontinuation for treatment failure
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Discontinuation for treatment failure
    7.7 % of cases
    exenatide

    Source sentences

    Summary
    Discontinuation for treatment failure occurred in 7.7% of cases (exenatide), 3.8% (sitagliptin), and 4.1% (vildagliptin), respectively, corresponding to 27-40% of all discontinuations, after excluding lost to follow-up.
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.
  3. 03HumanObservational studyEfficacy outcome

    In the Italian registry, exenatide treatment was linked to a 3.5% body weight decrease.

    In plain wordsIn the registry, exenatide treatment was linked to a 3.5% weight decrease.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Body weight decrease
    3.5%
    exenatide

    Source sentences

    Summary
    Body weight decreased by 3.5% with exenatide and by 1.0-1.5% with DPP-4 inhibitors.
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

Studies that did not test the peptide alone8

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 04HumanNot a test of Exenatide (exendin-4) aloneObservational studySafety outcome

    In the Italian registry, pooled exenatide, sitagliptin and vildagliptin treatment had 1116 suspected adverse drug reactions.

    In plain wordsIn the registry, the three drugs together had 1116 suspected adverse reactions.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSuspected adverse drug reactions across drugs
    Study

    n = 75,283

    Outcome group
    Adverse events · Whole body

    Measurements

    Suspected adverse drug reactions
    1116 reactions
    exenatide, sitagliptin and vildagliptin pooled

    Source sentences

    Summary
    Overall, 1116 suspected adverse drug reactions were registered, including 12 cases of acute pancreatitis (six on exenatide).
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 05HumanNot a test of Exenatide (exendin-4) aloneObservational studySafety outcome

    In the Italian registry of incretin treatments, hypoglycemia occurred mainly with sulfonylurea combinations, without a drug-specific estimate.

    In plain wordsIn the registry, low blood sugar occurred mainly with sulfonylurea combinations, without a separate exenatide estimate.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableHypoglycemia with sulfonylureas
    Study

    n = 75,283

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Hypoglycemic episodes mainly occurred in combination with sulfonylureas.
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 06HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In the pooled three-drug registry analysis, male sex was linked to less treatment discontinuation.

    In plain wordsAcross the three drugs, men had lower odds of stopping treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDiscontinuation association with sex
    Study

    n = 75,283

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Treatment discontinuation for the three drugs (logistic regression analysis) was negatively associated with the male gender and positively with baseline HbA1c, diabetes duration, and, limitedly to DPP-4 inhibitors, with BMI.
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 07HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In the pooled three-drug registry analysis, higher baseline HbA1c was linked to more treatment discontinuation.

    In plain wordsAcross the three drugs, higher starting HbA1c was linked to more treatment discontinuation.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDiscontinuation association with baseline HbA1c
    Study

    n = 75,283

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Treatment discontinuation for the three drugs (logistic regression analysis) was negatively associated with the male gender and positively with baseline HbA1c, diabetes duration, and, limitedly to DPP-4 inhibitors, with BMI.
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 08HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther

    In the pooled three-drug registry analysis, longer diabetes duration was linked to more treatment discontinuation.

    In plain wordsAcross the three drugs, longer diabetes duration was linked to more treatment discontinuation.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseDiscontinuation association with diabetes duration
    Study

    n = 75,283

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Treatment discontinuation for the three drugs (logistic regression analysis) was negatively associated with the male gender and positively with baseline HbA1c, diabetes duration, and, limitedly to DPP-4 inhibitors, with BMI.
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 09HumanNot a test of Exenatide (exendin-4) aloneObservational studySafety outcome

    In the pooled registry, treatment discontinuation (including loss to follow-up, accounting for 21-26%) was frequent.

    In plain wordsAcross the registry treatments, stopping treatment was frequent, including loss to follow-up.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableTreatment discontinuation and loss to follow-up
    Study

    n = 75,283

    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Accounting for (discontinuation including loss to follow-up, as written)
    21 to 26%
    exenatide, sitagliptin and vildagliptin pooled

    Source sentences

    Summary
    Treatment discontinuation (including loss to follow-up, accounting for 21-26%) was frequent.
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  7. 10HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome

    In the registry of exenatide, sitagliptin and vildagliptin, average HbA1c decreased by 0.9-1.0%, without a separate exenatide estimate.

    In plain wordsAcross the registry drugs, HbA1c decreased by 0.9-1.0%, without a separate exenatide result.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePooled HbA1c change
    Study

    n = 75,283

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c decrease
    0.9 to 1%
    exenatide, sitagliptin and vildagliptin pooled, average
    HbA1c decrease
    9 mmol/mol
    exenatide, sitagliptin and vildagliptin pooled, average

    Source sentences

    Summary
    HbA1c decreased on average by 0.9-1.0% (9 mmol/mol).
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  8. 11HumanNot a test of Exenatide (exendin-4) aloneObservational studySafety outcome

    In the Italian registry, 12 acute pancreatitis cases occurred across exenatide, sitagliptin and vildagliptin treatments.

    In plain wordsAcross the three registry drugs, patients had 12 acute pancreatitis cases, including six during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicablePooled acute pancreatitis cases
    Study

    n = 75,283

    Outcome group
    Adverse events · Gastrointestinal

    Measurements

    Acute pancreatitis cases
    12 cases
    exenatide, sitagliptin and vildagliptin pooled

    Source sentences

    Summary
    Overall, 1116 suspected adverse drug reactions were registered, including 12 cases of acute pancreatitis (six on exenatide).
    1 context sentence
    Summary · context
    From February 2008 to August 2010, 75,283 patients with type 2 diabetes were entered into the registry and treated with exenatide, sitagliptin, or vildagliptin.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.